VK
Live price temporarily unavailable.
Price history
Viking Therapeutics (VKTX) is a Health Care company in the Russell 1000. Latest news and coverage below.
IPO: April 29, 2015 · $8.00 offering · NASDAQ · View IPO details →
Viking Therapeutics revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$13.8M | −$19.1M | −$26.2M | −$32.7M | −$42.7M | −$55.7M | −$70.4M | −$100.8M | −$150.9M | −$393.3M |
| Net income | −$14.7M | −$20.6M | −$22.1M | −$25.8M | −$39.5M | −$55.0M | −$68.9M | −$85.9M | −$110.0M | −$359.6M |
| EPS (diluted) | −$0.90 | −$0.79 | −$0.38 | −$0.36 | −$0.54 | −$0.71 | −$0.90 | −$0.91 | −$1.01 | −$3.19 |
| Balance sheet | ||||||||||
| Cash and equivalents | $3.08M | $8.99M | $24.8M | $8.38M | $29.1M | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M |
| Total assets | $14.5M | $22.1M | $302.3M | $284.3M | $256.5M | $210.7M | $168.5M | $368.5M | $908.3M | $715.7M |
| Total liabilities | $6.49M | $8.66M | $4.56M | $7.14M | $12.2M | $8.78M | $23.2M | $20.1M | $28.0M | $76.7M |
| Shareholders' equity | $8.04M | $13.5M | $297.8M | $277.1M | $244.3M | $201.9M | $145.3M | $348.4M | $880.3M | $639.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$11.1M | −$14.8M | −$18.8M | −$24.8M | −$21.8M | −$47.6M | −$48.4M | −$73.4M | −$87.8M | −$278.7M |
| Share buybacks | $229 | — | — | — | — | — | $6.79M | — | — | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $0 | $0 | — | $0 | $0 |
| Operating income | −$36.6M | — | −$55.5M | −$74.6M | −$98.6M | — | −$164.1M | −$132.6M |
| Net income | −$24.9M | — | −$45.6M | −$65.6M | −$90.8M | — | −$158.3M | −$128.0M |
| EPS (diluted) | −$0.22 | — | −$0.41 | −$0.58 | −$0.81 | — | −$1.37 | −$1.10 |
| Balance sheet | ||||||||
| Cash and equivalents | $50.3M | $26.7M | $37.9M | $33.9M | $100.4M | $165.8M | $118.1M | $125.8M |
| Total assets | $937.9M | $908.3M | $867.0M | $827.9M | $739.4M | $715.7M | $608.2M | $521.9M |
| Total liabilities | $26.4M | $28.0M | $20.1M | $32.4M | $26.4M | $76.7M | $106.3M | $113.6M |
| Shareholders' equity | $911.4M | $880.3M | $846.9M | $795.5M | $713.0M | $639.1M | $501.9M | $408.3M |
| Cash flow | ||||||||
| Operating cash flow | −$22.0M | — | −$52.3M | −$47.1M | −$94.0M | — | −$114.0M | −$125.2M |
From Viking Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About Viking Therapeutics
- Headquarters
- San Diego, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International